{"gene":"PLK3","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1996,"finding":"PRK/PLK3 encodes a protein serine/threonine kinase with an N-terminal catalytic domain homologous to polo-family kinases (CDC5, Drosophila polo, PLK1) and a C-terminal regulatory domain; recombinant protein strongly phosphorylates casein but not histone H1 in vitro; expression is induced by serum and cytokines (IL-3, thrombopoietin) in hematopoietic cells without requiring new protein synthesis.","method":"cDNA cloning, in vitro kinase assay with recombinant protein, Northern blotting, serum/cytokine stimulation experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase reconstitution with recombinant protein, multiple orthogonal methods (cloning, kinase assay, expression analysis) in a single study","pmids":["8702627"],"is_preprint":false},{"year":1997,"finding":"Human PRK/PLK3 phosphorylates Cdc25C in vitro, peaks in kinase activity during late S and G2 phases, potentiates progesterone-induced meiotic maturation of Xenopus oocytes when overexpressed, delays oocyte maturation with antisense transcripts, and rescues the temperature-sensitive CDC5 mutant in S. cerevisiae, establishing a conserved mitotic regulatory role.","method":"In vitro kinase assay with recombinant baculovirus-expressed protein, Xenopus oocyte maturation assay, yeast complementation of cdc5 mutant, cell-cycle fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods including in vitro reconstitution, genetic rescue in yeast, and Xenopus functional assay across two model organisms","pmids":["9353331"],"is_preprint":false},{"year":1998,"finding":"Fnk/PLK3 protein is present in quiescent cells, increases in abundance from G1 to mitosis, undergoes mitotic-specific phosphorylation that causes a mobility shift and correlates with increased kinase activity; dephosphorylation by phosphatase treatment of mitotic immunoprecipitates reduces this activity, demonstrating phosphorylation-dependent kinase activation.","method":"SDS-PAGE mobility shift analysis, phosphatase treatment, immunoprecipitation kinase assay, cell-cycle synchronization","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal biochemical experiments (phosphatase reversal of kinase activation), single lab, two orthogonal methods","pmids":["9677325"],"is_preprint":false},{"year":1999,"finding":"Purified recombinant Prk/PLK3 directly phosphorylates Cdc25C in vitro on serine 216 (the major site also targeted by Chk1/Chk2); kinase-defective PrkK52R mutant cannot phosphorylate Cdc25C; Prk and Cdc25C physically interact by co-immunoprecipitation and affinity chromatography; when co-infected with Prk baculovirus, Cdc25C acquires autophosphorylating kinase activity dependent on catalytically active Prk.","method":"In vitro kinase assay with purified recombinant baculovirus proteins, co-immunoprecipitation, affinity chromatography, phosphopeptide mapping, active-site mutant (K52R)","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with purified recombinant proteins, active-site mutagenesis, co-IP, and phosphopeptide mapping in a single study","pmids":["10557092"],"is_preprint":false},{"year":1999,"finding":"Fnk/PLK3 interacts specifically with CIB (Ca2+- and integrin-binding protein) via a conserved C-terminal polo-box domain; Fnk and Snk mRNA levels are dramatically induced in neurons by stimuli that produce long-term potentiation; induced Fnk protein is targeted to dendrites of activated neurons.","method":"Two-hybrid screen, co-immunoprecipitation, co-localization in mammalian cells, LTP stimulation paradigms, subcellular fractionation/localization","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and co-localization confirm interaction, LTP induction is physiologically relevant but single lab","pmids":["10523297"],"is_preprint":false},{"year":2000,"finding":"Overexpression of PLK3 in mammalian cells induces chromatin condensation, apoptosis, and incomplete cytokinesis; EGFP-Plk3 localizes to the cellular cortex and cell midbody during mitotic exit, consistent with a cytokinesis role; Bcl-2 co-expression cannot block the apoptotic phenotype; the C-terminal domain (but not catalytic activity) is required for apoptosis induction.","method":"Transfection/overexpression, EGFP live-cell imaging, TUNEL assay, Bcl-2 co-expression epistasis, deletion/domain mutant analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization by live imaging linked to functional phenotype, domain dissection, single lab","pmids":["11156373"],"is_preprint":false},{"year":2001,"finding":"Plk3 physically interacts with p53, and this interaction is enhanced upon DNA damage; recombinant Plk3 phosphorylates a GST-p53 fusion in vitro on serine 20; expression of kinase-defective Plk3(K52R) reduces p53-S20 phosphorylation, decreases p21 levels, and increases cell proliferation; Plk3 kinase activity is rapidly induced by DNA damage in an ATM-dependent manner, while Plk1 activity is reduced; kinase-active Plk3 overexpression induces apoptosis.","method":"Co-immunoprecipitation, GST pull-down, in vitro kinase assay with recombinant proteins, immunoblotting with phosphospecific antibodies, ATM-dependent activation assay, kinase-dead mutant expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro phosphorylation, pulldown plus Co-IP, active-site mutagenesis with defined downstream functional readout (p21 levels, proliferation)","pmids":["11551930"],"is_preprint":false},{"year":2002,"finding":"Plk3 becomes phosphorylated following DNA damage (ATM-dependent) or mitotic spindle disruption (ATM-independent); phosphorylation enhances kinase activity; Plk3 physically associates with Chk2 and p53 and phosphorylates both as substrates; phosphorylated Plk3 also co-elutes with unpolymerized tubulin; Plk3 exists in multiple high-molecular-weight complexes (150–>600 kDa) whose composition changes upon phosphorylation.","method":"Sizing column fractionation, immunoprecipitation kinase assay, in vitro phosphorylation with recombinant proteins, ATM inhibition/genetic dependence, tubulin co-elution","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (kinase assay, size fractionation, Co-IP, ATM epistasis) identifying substrates and regulatory inputs","pmids":["12242661"],"is_preprint":false},{"year":2002,"finding":"Plk3 is rapidly activated by reactive oxygen species in normal diploid fibroblasts (WI-38), correlating with increased p53 levels; Plk3 physically interacts with Chk2 (enhanced by DNA damage); Chk2 immunoprecipitated from Plk3-expressing (T47D) cells stimulates the in vitro kinase activity of recombinant Plk3 more than Chk2 from Plk3-deficient (Daudi) cells; ectopic Chk2 expression activates cellular Plk3, placing Chk2 upstream of Plk3 in the DNA damage response.","method":"In vitro kinase assay with purified recombinant Plk3, co-immunoprecipitation, ectopic Chk2 expression, ROS treatment","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution with immunoprecipitated Chk2 stimulating recombinant Plk3, Co-IP, single lab","pmids":["12548019"],"is_preprint":false},{"year":2004,"finding":"Plk3 phosphorylates Cdc25C primarily on S191 and secondarily on S198 in vitro; a phosphomimetic S191D mutant accumulates in the nucleus while S191A facilitates nuclear exclusion; Plk3-WT overexpression drives Cdc25C nuclear accumulation and decreases Cdc2 Y15 phosphorylation; kinase-dead Plk3 overexpression fails to relocalize Cdc25C; the effect is reversed by Plk3 siRNA co-expression.","method":"In vitro kinase assay, transfection of phosphomimetic/phospho-null Cdc25C mutants, subcellular localization by immunofluorescence, immunoblotting for Cdc2-Y15, siRNA rescue","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro site mapping plus phosphomimetic mutagenesis plus functional rescue by siRNA across multiple orthogonal readouts","pmids":["14968113"],"is_preprint":false},{"year":2006,"finding":"Plk3 phosphorylates Chk2 at S62 and S73 in vitro; S73 phosphorylation by Plk3 facilitates subsequent ATM-dependent phosphorylation of Chk2 on T68 in response to DNA damage; Chk2-S73A mutant fails to associate with large complexes in vivo, has reduced kinase activity toward Cdc25C, is inefficiently phosphorylated at T68 by ATM, and cannot maintain G2/M checkpoint (Cdc2-Y15 hypophosphorylated); in Chk2-deficient Daudi cells, Chk2 kinase activity toward Cdc25C is weak and is restored dose-dependently by adding recombinant Plk3.","method":"In vitro kinase assay, site-directed mutagenesis (S73A), transfection/rescue, ATM epistasis, immunoprecipitation kinase assay, G2/M checkpoint assay","journal":"Mutation research","confidence":"High","confidence_rationale":"Tier 1 / Strong — site-specific mutagenesis validated functionally through G2/M checkpoint readout, in vitro reconstitution, genetic epistasis placing Plk3 upstream of ATM-mediated Chk2 activation","pmids":["16481012"],"is_preprint":false},{"year":2006,"finding":"The Polo box domain (PBD) of Plk3, requiring both polo boxes, is sufficient for centrosome, spindle pole, and midbody localization; overexpression of the PBD (but not the kinase domain) causes mitotic arrest, cytokinesis defects, and apoptosis; Plk3 PBD is more potent than Plk1 PBD in suppressing proliferation.","method":"Ectopic expression of domain constructs, immunofluorescence localization in HeLa and U2OS cells, cell-cycle analysis, apoptosis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization with domain deletions linked to defined mitotic phenotype, single lab","pmids":["16478733"],"is_preprint":false},{"year":2008,"finding":"Plk3 interacts with VRK1 (forming a stable complex detected by reciprocal immunoprecipitation and pull-down); VRK1 co-localizes with Plk3 at the Golgi apparatus; Plk3 phosphorylates the C-terminal region of VRK1 specifically at Ser342; VRK1-S342 substitution mutants are catalytically active but block Golgi fragmentation; Plk3 functions downstream of MEK1 and upstream of VRK1 in the Golgi fragmentation pathway; kinase-dead Plk3, VRK1 siRNA, or the MEK1 inhibitor PD98059 all inhibit MEK1/Plk3-induced Golgi fragmentation.","method":"Reciprocal co-immunoprecipitation, pull-down, immunofluorescence co-localization, in vitro kinase assay, site-directed mutagenesis (S342), siRNA knockdown, epistasis with MEK1 inhibitor and kinase-dead constructs","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reciprocal Co-IP, in vitro phosphorylation with site identification, mutagenesis with functional (Golgi fragmentation) readout, pathway epistasis by multiple independent perturbations","pmids":["19103756"],"is_preprint":false},{"year":2008,"finding":"Plk3 phosphorylates topoisomerase IIα at Thr1342 in vitro using a synthetic peptide and recombinant protein; Thr1342 is not recognized by Plk1; acidic residues at positions +2 and +4 relative to the phosphosite are positive determinants for Plk3 but not Plk1 specificity; Plk3 overexpression induces Thr1342 phosphorylation in cellular topoisomerase IIα; Plk3 and topoisomerase IIα physically interact in cells.","method":"In vitro kinase assay with synthetic peptides, co-immunoprecipitation in cells, immunoblotting with phosphospecific antibody, overexpression","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis of substrate determinants plus cellular co-IP validation, single lab","pmids":["18062778"],"is_preprint":false},{"year":2009,"finding":"Plk3 physically interacts with p73 (by co-immunoprecipitation and GST pull-down); Plk3 phosphorylates the N-terminal portion of p73 in vitro; Plk3 inhibits p73-mediated transcriptional activity and pro-apoptotic function; kinase-deficient Plk3 fails to inhibit p73, demonstrating kinase-activity dependence; Plk3 reduces p73 protein stability; Plk3 knockdown increases p73 stability and promotes cisplatin-induced apoptosis.","method":"Co-immunoprecipitation, GST pull-down, in vitro kinase assay, luciferase reporter assay, RT-PCR, kinase-dead mutant, siRNA knockdown, flow cytometry (apoptosis)","journal":"Genes to cells : devoted to molecular & cellular mechanisms","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro phosphorylation plus Co-IP plus kinase-dead epistasis with functional readout, single lab","pmids":["19490146"],"is_preprint":false},{"year":2010,"finding":"Plk3 physically interacts with HIF-1α under hypoxia (by immunoprecipitation and pull-down); purified recombinant Plk3, but not a kinase-defective mutant, phosphorylates HIF-1α in vitro causing a major mobility shift; mass spectrometry identified two serine residues as Plk3 phosphorylation sites; phosphomutant HIF-1α has a much longer half-life than wild-type, demonstrating Plk3 promotes HIF-1α degradation; PLK3-null MEFs contain elevated HIF-1α under hypoxia.","method":"Immunoprecipitation, pull-down, in vitro kinase assay with purified recombinant Plk3, mass spectrometry, cycloheximide chase/pulse-chase, PLK3-null MEFs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro kinase assay, mass spectrometry site identification, phosphomutant half-life analysis, and genetic null validation (multiple orthogonal methods, one study)","pmids":["20889502"],"is_preprint":false},{"year":2010,"finding":"Plk3 phosphorylates PTEN in vitro at Thr366 and Ser370 (identified by mass spectrometry and confirmed by phosphospecific antibody); kinase-defective Plk3 mutant cannot phosphorylate PTEN; PLK3-null MEFs have reduced PTEN levels and increased Akt1 activation; Plk3-targeting PTEN mutants are expressed at reduced levels associated with enhanced PDK1 activity; the reduced PTEN in PLK3-null MEFs is stabilized by the proteasome inhibitor MG132, demonstrating Plk3 phosphorylation stabilizes PTEN.","method":"In vitro kinase assay, mass spectrometry, phosphospecific immunoblotting, PLK3-null MEFs, kinase-dead mutant, MG132 proteasome inhibitor treatment, Akt/GSK3β activation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, mass spectrometry site identification, genetic null validation, proteasome inhibitor rescue, multiple orthogonal methods in one study","pmids":["20940307"],"is_preprint":false},{"year":2012,"finding":"In vitro PLK3 phosphorylates HSP90, GRP-94, β-tubulin, calumenin, and 14-3-3 epsilon in cell lysate kinase assays; phosphosites in these substrates were mapped by mass spectrometry and used to define PLK3 substrate consensus determinants as acidophilic (requiring acidic residues surrounding the target Ser/Thr).","method":"Cell lysate kinase assay, 2D gel electrophoresis, mass spectrometry substrate identification and phosphosite mapping","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mass spectrometry site identification, single lab, multiple substrates validated","pmids":["22828320"],"is_preprint":false},{"year":2013,"finding":"PRK3 HR1a and HR1b domains bind RhoA, RhoB, and RhoC with different affinities; PRK3 HR1b domain uniquely mediates a RhoB-specific interaction requiring both the C-terminus of RhoB and the HR1b domain; RhoB binds all PRK isoforms with higher affinity than RhoA or RhoC; the PRK2/PRK3 HR1 domains generally bind Rho proteins less tightly than PRK1.","method":"Quantitative binding affinity measurements (surface plasmon resonance or equivalent), thermal stability assays, domain constructs encompassing HR1a and HR1b","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — quantitative binding measurements with domain constructs defining specificity determinants, single lab study","pmids":["24128008"],"is_preprint":false},{"year":2016,"finding":"PLK3 is identified as a new interaction partner of the death receptor CD95; PLK3 enzymatic activity increases upon CD95 ligand stimulation; knockout of caspase-8, CD95, or FADD prevents PLK3 activation, establishing requirement for a functional DISC; PLK3 phosphorylates caspase-8 at Thr273, stimulating its pro-apoptotic function; non-phosphorylatable caspase-8-T273A mutant or PLK3 CRISPR/Cas9 knockout reduces caspase-8 processing after CD95 stimulation.","method":"Co-immunoprecipitation, CRISPR/Cas9 knockout, kinase activity assay, site-directed mutagenesis (T273A rescue experiment), genetic epistasis (CD95/FADD/caspase-8 KO)","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR KO, mutagenesis rescue, Co-IP, and kinase activity assay with multiple genetic epistasis experiments identifying substrate and pathway position","pmids":["27325299"],"is_preprint":false},{"year":2016,"finding":"Hypoxic stress activates Plk3 signaling and c-Jun/AP-1 in corneal epithelial cells leading to apoptosis, but suppresses Plk3 activity at the transcription level in limbal stem cells (HLS), resulting in differentiation instead of apoptosis; hypoxia-induced c-Jun phosphorylation is not observed in HLS cells because Plk3 is suppressed; Plk3-deficient (Plk3-/-) mouse corneas show altered limbal stem cell differentiation and center epithelial apoptosis patterns confirming pathway dependence.","method":"Plk3-/- mouse model, DNA fragmentation, TUNEL assay, cell cycle analysis, p63/keratin 12 expression, c-Jun phosphorylation, gene expression analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null mouse validated alongside mechanistic measurements in primary cells, single lab","pmids":["27281822"],"is_preprint":false},{"year":2020,"finding":"PLK3 interacts with the PP6 (protein phosphatase 6) complex via its polo box domain; PLK3 is phosphorylated at Thr219 in its T-loop; PP6 constantly dephosphorylates Thr219; unlike PLK1, phosphorylation of PLK3-Thr219 does not upregulate enzymatic activity, indicating distinct activation mechanisms between PLK1 and PLK3; CRISPR/Cas9-generated PLK3 knockout cells do not show impaired HIF-1α stabilization under hypoxia, p-c-Jun under osmotic stress, or DNA damage response dynamics.","method":"CRISPR/Cas9 knockout in RPE cells, mass spectrometry (PP6 as interactor), immunoprecipitation, in vitro kinase assay with purified EGFP-PLK3, phosphospecific immunoblotting (T219), RNAi knockdown","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — mass spectrometry identification of PP6 interaction, in vitro kinase assay, CRISPR KO, single lab; negative findings explicitly noted","pmids":["32575753"],"is_preprint":false},{"year":2021,"finding":"PLK3 phosphorylates GOF mutant p53 at serine 20; PLK3 knockout attenuates S20 phosphorylation and reduces transactivation and oncogenicity by GOF p53; GOF p53 TAD mutations (L25Q/W26S) that reduce S20 phosphorylation lose tumorigenicity; these data place PLK3-mediated S20 phosphorylation as mechanistically required for GOF p53-driven oncogenesis.","method":"PLK3 knockout mouse model, conditional knock-in alleles (LSL p53-R172H, K-Ras-G12D), phosphospecific immunoblotting for p53-S20, transactivation assays, tumor growth analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout in vivo with phosphospecific readout and functional (tumor) phenotype, single study","pmids":["33514736"],"is_preprint":false},{"year":2023,"finding":"PLK3 interacts with viral nucleoprotein (NP) of swine influenza H1N1; PLK3 overexpression increases NP phosphorylation and oligomerization; PLK3 phosphorylates NP at serine 482 (S482), and S482 phosphorylation regulates NP oligomerization, viral polymerase activity, and viral growth.","method":"Co-immunoprecipitation, in vitro phosphorylation assay, site-directed mutagenesis (S482), viral polymerase activity assay, viral growth assay","journal":"Emerging microbes & infections","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with site mutagenesis plus functional viral readout, single lab","pmids":["37874309"],"is_preprint":false},{"year":2024,"finding":"SETDB1 methylates PLK3 at K106 and K200 (scaffolded by the lncRNA LINC00115); PLK3 methylation decreases PLK3 phosphorylation of HIF1α and increases HIF1α stability in drug-resistant breast cancer stem-like cells; this establishes SETDB1-mediated lysine methylation as a post-translational modification that suppresses PLK3 kinase activity toward HIF1α.","method":"RNA pull-down, RNA immunoprecipitation, mass spectrometry, CRISPR/Cas9 knockout, methylation-specific assays, HIF1α stability assays","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry identification of methylation sites, CRISPR KO, functional HIF1α stability readout; single lab, complex multi-component system","pmids":["38520019"],"is_preprint":false},{"year":2021,"finding":"miR-24 directly targets Plk3 mRNA in hair follicle progenitors; miR-24 upregulation blunts growth responsiveness and retards hair regeneration, while its ablation leads to hyper-sensitized growth responsiveness and precocious hair regeneration; reduced Plk3 downstream of miR-24 leads to decreased CCNE1 (cyclin E1) expression, limiting cell-cycle entry.","method":"miR-24 conditional overexpression and ablation in skin epithelium, target validation (miR-24 → Plk3), cell-cycle analysis, CCNE1 expression measurement, in vivo hair regeneration assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic gain- and loss-of-function with direct target validation, in vivo phenotype, single lab","pmids":["34107258"],"is_preprint":false},{"year":2023,"finding":"TUBA1A (tubulin alpha 1a) interacts with PLK3 in the cytoplasm and inhibits its activation; this interaction licenses APC/C activation and Foxm1-mediated metaphase-to-anaphase transition; TUBA1A knockdown causes mitotic arrest and reduces GBM tumor growth in a PLK3-dependent manner.","method":"Co-immunoprecipitation, TUBA1A knockdown, PLK3 activation assays, APC/C activity assays, xenograft tumor growth assay","journal":"FEBS letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP identifying interaction, functional epistasis from knockdown, but mechanistic detail on PLK3 activation mechanism is limited and single lab","pmids":["37873730"],"is_preprint":false}],"current_model":"PLK3 (also known as PRK/FNK) is a polo-family serine/threonine kinase activated by ATM-dependent phosphorylation (at T219 in the T-loop, dephosphorylated by PP6) in response to genotoxic and oxidative stress; it phosphorylates a defined set of substrates—including Cdc25C (at S191/S216 to control nuclear translocation and cell cycle entry), p53 (at S20 to stabilize it and activate apoptotic/arrest programs), Chk2 (at S62/S73 to prime ATM-mediated full Chk2 activation), HIF-1α (to promote its proteasomal degradation under hypoxia), PTEN (at T366/S370 to stabilize it and suppress PI3K/Akt signaling), VRK1 (at S342 downstream of MEK1 to drive Golgi fragmentation), topoisomerase IIα (at T1342), caspase-8 (at T273 downstream of CD95/DISC to amplify extrinsic apoptosis), and influenza NP (at S482)—localizing to centrosomes, spindle poles, and the midbody via its polo box domain; it is negatively regulated by SETDB1-mediated methylation (at K106/K200) and by inhibitory interaction with TUBA1A, and is transcriptionally regulated by stress, serum, and cytokines, collectively functioning as a multi-substrate stress-response and cell-cycle checkpoint kinase with tumor-suppressive activity."},"narrative":{"mechanistic_narrative":"PLK3 (PRK/FNK) is a polo-family serine/threonine kinase that functions as a multi-substrate effector coupling genotoxic, oxidative, hypoxic, and death-receptor stress signals to cell-cycle checkpoints and apoptosis [PMID:8702627, PMID:12242661]. Its catalytic activity is rapidly induced by DNA damage in an ATM-dependent manner and by reactive oxygen species, and is enhanced by mitotic-specific and stress-induced phosphorylation [PMID:9677325, PMID:11551930, PMID:12242661, PMID:12548019]. Within the DNA-damage checkpoint PLK3 phosphorylates Cdc25C on S191/S216 to control its nuclear accumulation and entry into mitosis, phosphorylates p53 on S20 to stabilize it and drive p21 induction and apoptosis, and primes Chk2 at S62/S73 to facilitate downstream ATM-mediated Chk2 activation and G2/M arrest [PMID:10557092, PMID:11551930, PMID:14968113, PMID:16481012]; Chk2 itself acts upstream of PLK3 in this circuit [PMID:12548019]. PLK3 has broad acidophilic substrate specificity and additional targets that extend its reach beyond the checkpoint: it phosphorylates HIF-1α to promote its proteasomal degradation under hypoxia, phosphorylates PTEN at T366/S370 to stabilize it and suppress Akt signaling, phosphorylates topoisomerase IIα at T1342, inhibits p73, and phosphorylates caspase-8 at T273 downstream of the CD95 DISC to amplify extrinsic apoptosis [PMID:18062778, PMID:19490146, PMID:20889502, PMID:20940307, PMID:22828320, PMID:27325299]. Its tandem polo-box domain targets the enzyme to centrosomes, spindle poles, and the midbody and is itself sufficient to drive mitotic arrest and apoptosis [PMID:16478733], and via this domain PLK3 also acts downstream of MEK1 to phosphorylate VRK1 at S342 and drive Golgi fragmentation [PMID:19103756]. PLK3 is negatively controlled by PP6, which constitutively dephosphorylates its T-loop T219, and by SETDB1-mediated lysine methylation that suppresses its activity toward HIF-1α [PMID:32575753, PMID:38520019]. Genetic models establish PLK3 as a determinant of tumor biology and tissue homeostasis, including a requirement for PLK3-mediated p53-S20 phosphorylation in gain-of-function mutant p53 oncogenesis [PMID:33514736] and a miR-24/PLK3/cyclin E1 axis controlling cell-cycle entry in regenerating tissue [PMID:34107258].","teleology":[{"year":1996,"claim":"Established PLK3 as a polo-family serine/threonine kinase whose expression is acutely driven by extracellular growth and cytokine signals, framing it as a stimulus-responsive kinase.","evidence":"cDNA cloning, in vitro kinase assay on recombinant protein, and serum/cytokine induction in hematopoietic cells","pmids":["8702627"],"confidence":"High","gaps":["Physiological substrates unidentified at this stage","Casein used as generic substrate, not a real target","Regulation of kinase activity unknown"]},{"year":1997,"claim":"Defined a conserved mitotic regulatory role by showing PLK3 phosphorylates Cdc25C, peaks in S/G2, and functionally substitutes for yeast CDC5.","evidence":"In vitro kinase assay, Xenopus oocyte maturation, yeast cdc5 complementation, cell-cycle fractionation","pmids":["9353331"],"confidence":"High","gaps":["Specific Cdc25C phosphosites not yet mapped","How PLK3 activity is timed to the cell cycle unresolved"]},{"year":1998,"claim":"Demonstrated that PLK3 activity is controlled by phosphorylation, linking mitotic-specific modification to increased catalytic output.","evidence":"Mobility-shift analysis, phosphatase reversal of immunoprecipitate kinase activity, cell-cycle synchronization","pmids":["9677325"],"confidence":"Medium","gaps":["Activating phosphosite and responsible kinase not identified","Single lab"]},{"year":1999,"claim":"Pinned down Cdc25C serine 216 as a direct PLK3 site and showed physical PLK3-Cdc25C association, connecting PLK3 to the checkpoint phosphosite shared with Chk1/Chk2.","evidence":"Purified recombinant kinase assay, K52R kinase-dead mutant, co-IP, affinity chromatography, phosphopeptide mapping","pmids":["10557092"],"confidence":"High","gaps":["In vivo consequence of S216 phosphorylation on checkpoint not directly tested","Relationship to Chk1/Chk2 targeting of the same site unresolved"]},{"year":1999,"claim":"Identified the C-terminal polo-box domain as a protein-interaction module (binding CIB) and showed stimulus-driven neuronal induction and dendritic targeting, expanding PLK3 beyond cell cycle.","evidence":"Two-hybrid screen, co-IP, co-localization, LTP stimulation paradigms","pmids":["10523297"],"confidence":"Medium","gaps":["Functional consequence of CIB binding unknown","Neuronal substrate not defined"]},{"year":2000,"claim":"Linked PLK3 to cytokinesis and apoptosis through midbody/cortex localization, and showed the C-terminal domain rather than catalytic activity drives the apoptotic phenotype.","evidence":"Overexpression, EGFP live imaging, TUNEL, Bcl-2 epistasis, domain mutants","pmids":["11156373"],"confidence":"Medium","gaps":["Overexpression may not reflect endogenous function","Mechanism by which the C-terminal domain triggers apoptosis unresolved"]},{"year":2001,"claim":"Placed PLK3 in the ATM-dependent DNA-damage response as a direct p53 S20 kinase that stabilizes p53 and enforces growth suppression.","evidence":"Co-IP, GST pull-down, in vitro kinase assay, phosphospecific blotting, ATM-dependence, K52R mutant, p21/proliferation readouts","pmids":["11551930"],"confidence":"High","gaps":["Direct ATM target on PLK3 not mapped","Quantitative contribution to p53 stabilization versus other kinases unresolved"]},{"year":2002,"claim":"Resolved the regulatory architecture of PLK3 activation by distinguishing ATM-dependent (DNA damage) from ATM-independent (spindle disruption) phosphorylation and identifying Chk2 and p53 as substrates within high-molecular-weight complexes.","evidence":"Sizing-column fractionation, IP kinase assays, in vitro phosphorylation, ATM epistasis, tubulin co-elution","pmids":["12242661"],"confidence":"High","gaps":["Composition of the >600 kDa complexes not defined","Direct activating phosphosite still unmapped"]},{"year":2002,"claim":"Showed reciprocal regulation with Chk2, placing Chk2 upstream as an activator of PLK3 during the oxidative/DNA-damage response.","evidence":"ROS treatment, in vitro kinase assay with immunoprecipitated Chk2 stimulating recombinant PLK3, co-IP, ectopic Chk2 expression","pmids":["12548019"],"confidence":"Medium","gaps":["Whether Chk2 activates PLK3 directly or via complex assembly unclear","Single lab"]},{"year":2004,"claim":"Established the functional output of PLK3-Cdc25C phosphorylation by mapping S191/S198 and showing phosphorylation controls Cdc25C nuclear accumulation and Cdc2-Y15 status.","evidence":"In vitro kinase assay, phosphomimetic/phospho-null Cdc25C mutants, immunofluorescence, Cdc2-Y15 blotting, siRNA rescue","pmids":["14968113"],"confidence":"High","gaps":["Endogenous timing of PLK3 action on Cdc25C during checkpoint recovery not addressed"]},{"year":2006,"claim":"Positioned PLK3 upstream of ATM-mediated Chk2 activation by showing PLK3 phosphorylation of Chk2 S73 primes T68 phosphorylation and is required for G2/M checkpoint maintenance.","evidence":"In vitro kinase assay, S73A mutant, rescue, ATM epistasis, IP kinase assay, G2/M checkpoint assay, recombinant PLK3 rescue in Chk2-deficient cells","pmids":["16481012"],"confidence":"High","gaps":["Order of PLK3 vs ATM action in vivo not fully time-resolved","How PLK3 itself becomes activated upstream of Chk2 unresolved"]},{"year":2006,"claim":"Defined the tandem polo-box domain as both the localization determinant (centrosome/spindle pole/midbody) and a sufficient driver of mitotic arrest and apoptosis.","evidence":"Domain construct expression, immunofluorescence in HeLa/U2OS, cell-cycle and apoptosis assays","pmids":["16478733"],"confidence":"Medium","gaps":["Phosphopeptide ligands recognized by the PBD in vivo not identified","Overexpression-based phenotypes"]},{"year":2008,"claim":"Extended PLK3 signaling to Golgi dynamics by identifying VRK1-S342 as a substrate and placing PLK3 between MEK1 and VRK1 in the Golgi fragmentation pathway.","evidence":"Reciprocal co-IP, pull-down, co-localization, in vitro kinase assay, S342 mutagenesis, siRNA, MEK1 inhibitor epistasis","pmids":["19103756"],"confidence":"High","gaps":["Physiological trigger for MEK1-PLK3-VRK1 Golgi pathway unclear","How PLK3 is recruited to Golgi not defined"]},{"year":2008,"claim":"Defined PLK3 acidophilic substrate specificity by mapping topoisomerase IIα T1342 and showing the +2/+4 acidic determinants distinguish PLK3 from PLK1.","evidence":"In vitro kinase assay with synthetic peptides, co-IP, phosphospecific blotting, overexpression","pmids":["18062778"],"confidence":"Medium","gaps":["Cellular consequence of T1342 phosphorylation on topoisomerase IIα function not established"]},{"year":2009,"claim":"Showed PLK3 negatively regulates the p53-family member p73 by phosphorylation, reducing its stability and pro-apoptotic transcriptional activity.","evidence":"Co-IP, GST pull-down, in vitro kinase assay, luciferase reporter, kinase-dead mutant, siRNA, flow cytometry","pmids":["19490146"],"confidence":"Medium","gaps":["Phosphosite on p73 not mapped","Reconciliation with PLK3 pro-apoptotic roles elsewhere unresolved"]},{"year":2010,"claim":"Connected PLK3 to hypoxia by showing it phosphorylates HIF-1α to promote its degradation, with genetic null cells accumulating HIF-1α.","evidence":"IP/pull-down, recombinant kinase assay, mass spectrometry sites, half-life analysis, PLK3-null MEFs","pmids":["20889502"],"confidence":"High","gaps":["Mechanism linking phosphorylation to proteasomal targeting not detailed","Later KO study found no HIF-1α phenotype, indicating context dependence"]},{"year":2010,"claim":"Identified PLK3 as a positive regulator of PTEN stability via T366/S370 phosphorylation, linking it to suppression of PI3K/Akt signaling.","evidence":"In vitro kinase assay, mass spectrometry, phosphospecific blotting, PLK3-null MEFs, MG132 rescue, Akt/GSK3β assays","pmids":["20940307"],"confidence":"High","gaps":["E3 ligase/proteasomal machinery acting on unphosphorylated PTEN not identified"]},{"year":2012,"claim":"Generalized the PLK3 acidophilic consensus by identifying additional in vitro substrates (HSP90, GRP-94, β-tubulin, calumenin, 14-3-3ε) and mapping their phosphosites.","evidence":"Cell-lysate kinase assay, 2D gel, mass spectrometry phosphosite mapping","pmids":["22828320"],"confidence":"Medium","gaps":["In vivo relevance of these substrates not tested","Lysate assay may capture indirect phosphorylation"]},{"year":2013,"claim":"Characterized Rho-binding specificity of PRK3 HR1 domains, defining a RhoB-selective interaction module.","evidence":"Quantitative binding affinity measurements and thermal stability assays with HR1a/HR1b constructs","pmids":["24128008"],"confidence":"Medium","gaps":["Functional consequence of Rho binding for PLK3 signaling unaddressed","Note: this finding may reflect a distinct PRK protein family and is not integrated with the kinase activity literature"]},{"year":2016,"claim":"Placed PLK3 within extrinsic apoptosis as a DISC-dependent caspase-8 T273 kinase that amplifies CD95-induced cell death.","evidence":"Co-IP, CRISPR/Cas9 KO, kinase activity assay, T273A rescue, CD95/FADD/caspase-8 KO epistasis","pmids":["27325299"],"confidence":"High","gaps":["How DISC formation activates PLK3 catalytically not resolved"]},{"year":2016,"claim":"Demonstrated cell-type-specific hypoxic outcomes governed by PLK3 transcriptional control, dictating apoptosis versus differentiation in corneal epithelium.","evidence":"Plk3-/- mouse corneas, TUNEL, cell-cycle analysis, p63/keratin 12 and c-Jun phosphorylation readouts","pmids":["27281822"],"confidence":"Medium","gaps":["Transcriptional regulators suppressing Plk3 in limbal stem cells not identified","Direct substrate driving c-Jun phosphorylation unclear"]},{"year":2020,"claim":"Revised the PLK3 activation model by identifying PP6 as a T-loop (T219) phosphatase and showing, unlike PLK1, T219 phosphorylation does not boost activity; CRISPR KO failed to reproduce several reported stress phenotypes.","evidence":"CRISPR KO in RPE cells, mass spectrometry (PP6), IP, recombinant kinase assay, T219 phosphospecific blotting, RNAi","pmids":["32575753"],"confidence":"Medium","gaps":["Discrepancy with earlier HIF-1α/DNA-damage phenotypes unresolved","True T-loop activation mechanism of PLK3 still undefined"]},{"year":2021,"claim":"Established PLK3-mediated p53-S20 phosphorylation as mechanistically required for gain-of-function mutant p53 oncogenesis in vivo.","evidence":"PLK3 KO mouse, conditional LSL p53-R172H/K-Ras-G12D alleles, p53-S20 phosphospecific blotting, transactivation and tumor growth assays","pmids":["33514736"],"confidence":"Medium","gaps":["How the same S20 phosphorylation supports both tumor suppression and GOF oncogenesis context-dependently unresolved"]},{"year":2021,"claim":"Defined a miR-24/PLK3/cyclin E1 axis controlling cell-cycle entry and tissue regeneration in hair follicle progenitors.","evidence":"miR-24 conditional gain/loss of function, target validation, CCNE1 measurement, in vivo hair regeneration assay","pmids":["34107258"],"confidence":"Medium","gaps":["Direct PLK3 substrate linking to CCNE1 induction not identified"]},{"year":2023,"claim":"Showed PLK3 phosphorylates influenza nucleoprotein at S482 to regulate NP oligomerization, polymerase activity, and viral growth, identifying a host-kinase role in viral replication.","evidence":"Co-IP, in vitro phosphorylation, S482 mutagenesis, polymerase and viral growth assays","pmids":["37874309"],"confidence":"Medium","gaps":["Whether PLK3 is recruited to viral ribonucleoprotein in infected cells not shown"]},{"year":2023,"claim":"Proposed TUBA1A as a cytoplasmic inhibitor of PLK3 that gates APC/C and Foxm1-driven mitotic transition in glioblastoma.","evidence":"Co-IP, TUBA1A knockdown, PLK3 activation assays, APC/C assays, xenograft growth","pmids":["37873730"],"confidence":"Low","gaps":["Mechanism of PLK3 activation/inhibition by TUBA1A poorly defined","Single lab, Co-IP without reciprocal validation"]},{"year":2024,"claim":"Identified SETDB1-mediated lysine methylation (K106/K200), scaffolded by lncRNA LINC00115, as a post-translational brake on PLK3 activity toward HIF-1α in drug-resistant breast cancer stem-like cells.","evidence":"RNA pull-down/RIP, mass spectrometry, CRISPR KO, methylation-specific and HIF-1α stability assays","pmids":["38520019"],"confidence":"Medium","gaps":["How methylation mechanistically impairs catalysis not defined","Complex multi-component system, single lab"]},{"year":null,"claim":"The true physiological activation mechanism of PLK3 and the reconciliation of conflicting stress-response phenotypes across genetic models remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Activating upstream kinase/event for endogenous PLK3 unmapped given that T219 phosphorylation does not enhance activity","Discrepancy between PLK3-null MEF phenotypes and CRISPR KO negative results for HIF-1α/DNA damage unexplained","Structural basis of polo-box-mediated substrate/localization targeting not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,6,9,10,12,13,15,16,19]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,3,17]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[13]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[7,26]}],"localization":[{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[11]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[12]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[7,26]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,9,10,26]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[6,7,10]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,19,20]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[7,8,15,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,16]}],"complexes":["PP6 phosphatase complex"],"partners":["CDC25C","TP53","CHEK2","VRK1","HIF1A","PTEN","CASP8","PPP6C"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H4B4","full_name":"Serine/threonine-protein kinase PLK3","aliases":["Cytokine-inducible serine/threonine-protein kinase","FGF-inducible kinase","Polo-like kinase 3","PLK-3","Proliferation-related kinase"],"length_aa":646,"mass_kda":71.6,"function":"Serine/threonine-protein kinase involved in cell cycle regulation, response to stress and Golgi disassembly. Polo-like kinases act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates ATF2, BCL2L1, CDC25A, CDC25C, CHEK2, HIF1A, JUN, p53/TP53, p73/TP73, PTEN, TOP2A and VRK1. Involved in cell cycle regulation: required for entry into S phase and cytokinesis. Phosphorylates BCL2L1, leading to regulate the G2 checkpoint and progression to cytokinesis during mitosis. Plays a key role in response to stress: rapidly activated upon stress stimulation, such as ionizing radiation, reactive oxygen species (ROS), hyperosmotic stress, UV irradiation and hypoxia. Involved in DNA damage response and G1/S transition checkpoint by phosphorylating CDC25A, p53/TP53 and p73/TP73. Phosphorylates p53/TP53 in response to reactive oxygen species (ROS), thereby promoting p53/TP53-mediated apoptosis. Phosphorylates CHEK2 in response to DNA damage, promoting the G2/M transition checkpoint. Phosphorylates the transcription factor p73/TP73 in response to DNA damage, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates HIF1A and JUN is response to hypoxia. Phosphorylates ATF2 following hyperosmotic stress in corneal epithelium. Also involved in Golgi disassembly during the cell cycle: part of a MEK1/MAP2K1-dependent pathway that induces Golgi fragmentation during mitosis by mediating phosphorylation of VRK1. May participate in endomitotic cell cycle, a form of mitosis in which both karyokinesis and cytokinesis are interrupted and is a hallmark of megakaryocyte differentiation, via its interaction with CIB1","subcellular_location":"Cytoplasm; Nucleus; Nucleus, nucleolus; Golgi apparatus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome","url":"https://www.uniprot.org/uniprotkb/Q9H4B4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLK3","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLK3","total_profiled":1310},"omim":[{"mim_id":"607023","title":"POLO-LIKE KINASE 2; PLK2","url":"https://www.omim.org/entry/607023"},{"mim_id":"602913","title":"POLO-LIKE KINASE 3; PLK3","url":"https://www.omim.org/entry/602913"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PLK3"},"hgnc":{"alias_symbol":["FNK","PRK"],"prev_symbol":["CNK"]},"alphafold":{"accession":"Q9H4B4","domains":[{"cath_id":"3.30.200.20","chopping":"55-141","consensus_level":"high","plddt":93.5505,"start":55,"end":141},{"cath_id":"1.10.510.10","chopping":"146-328","consensus_level":"high","plddt":95.6717,"start":146,"end":328},{"cath_id":"3.30.1120.30","chopping":"428-643","consensus_level":"medium","plddt":87.6016,"start":428,"end":643}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4B4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4B4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4B4-F1-predicted_aligned_error_v6.png","plddt_mean":79.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLK3","jax_strain_url":"https://www.jax.org/strain/search?query=PLK3"},"sequence":{"accession":"Q9H4B4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H4B4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H4B4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4B4"}},"corpus_meta":[{"pmid":"12589777","id":"PMC_12589777","title":"Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK.","date":"2003","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/12589777","citation_count":331,"is_preprint":false},{"pmid":"19772257","id":"PMC_19772257","title":"Comparison of sequential vs same-day simultaneous collagen cross-linking and topography-guided PRK for treatment of keratoconus.","date":"2009","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/19772257","citation_count":226,"is_preprint":false},{"pmid":"17667633","id":"PMC_17667633","title":"Collagen cross-linking (CCL) with sequential topography-guided PRK: a temporizing alternative for keratoconus to penetrating keratoplasty.","date":"2007","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/17667633","citation_count":213,"is_preprint":false},{"pmid":"11551930","id":"PMC_11551930","title":"Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11551930","citation_count":181,"is_preprint":false},{"pmid":"10523297","id":"PMC_10523297","title":"The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10523297","citation_count":176,"is_preprint":false},{"pmid":"9678420","id":"PMC_9678420","title":"Neutralizing antibody to TGFbeta modulates stromal fibrosis but not regression of photoablative effect following PRK.","date":"1998","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/9678420","citation_count":145,"is_preprint":false},{"pmid":"21117539","id":"PMC_21117539","title":"Management of corneal ectasia after LASIK with combined, same-day, topography-guided partial transepithelial PRK and collagen cross-linking: the athens protocol.","date":"2010","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/21117539","citation_count":145,"is_preprint":false},{"pmid":"10967044","id":"PMC_10967044","title":"Modulation of acute inflammation and keratocyte death by suturing, blood, and amniotic membrane in PRK.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10967044","citation_count":138,"is_preprint":false},{"pmid":"8702627","id":"PMC_8702627","title":"Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702627","citation_count":127,"is_preprint":false},{"pmid":"12242661","id":"PMC_12242661","title":"Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12242661","citation_count":119,"is_preprint":false},{"pmid":"26384350","id":"PMC_26384350","title":"Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26384350","citation_count":106,"is_preprint":false},{"pmid":"12514133","id":"PMC_12514133","title":"A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12514133","citation_count":92,"is_preprint":false},{"pmid":"9353331","id":"PMC_9353331","title":"Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9353331","citation_count":90,"is_preprint":false},{"pmid":"23872360","id":"PMC_23872360","title":"Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery.","date":"2013","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/23872360","citation_count":88,"is_preprint":false},{"pmid":"25915845","id":"PMC_25915845","title":"The role of Plk3 in oncogenesis.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25915845","citation_count":86,"is_preprint":false},{"pmid":"20889502","id":"PMC_20889502","title":"Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20889502","citation_count":83,"is_preprint":false},{"pmid":"11156373","id":"PMC_11156373","title":"Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11156373","citation_count":77,"is_preprint":false},{"pmid":"12548019","id":"PMC_12548019","title":"Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2.","date":"2002","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/12548019","citation_count":68,"is_preprint":false},{"pmid":"14968113","id":"PMC_14968113","title":"Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14968113","citation_count":65,"is_preprint":false},{"pmid":"10557092","id":"PMC_10557092","title":"The physical association and phosphorylation of Cdc25C protein phosphatase by Prk.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10557092","citation_count":56,"is_preprint":false},{"pmid":"20940307","id":"PMC_20940307","title":"Regulation of PTEN stability and activity by Plk3.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20940307","citation_count":55,"is_preprint":false},{"pmid":"11095603","id":"PMC_11095603","title":"Measurement of mRNAs for TGFss and extracellular matrix proteins in corneas of rats after PRK.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11095603","citation_count":55,"is_preprint":false},{"pmid":"19103756","id":"PMC_19103756","title":"Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19103756","citation_count":52,"is_preprint":false},{"pmid":"10679924","id":"PMC_10679924","title":"PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer.","date":"2000","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10679924","citation_count":52,"is_preprint":false},{"pmid":"16478733","id":"PMC_16478733","title":"Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16478733","citation_count":51,"is_preprint":false},{"pmid":"38520019","id":"PMC_38520019","title":"LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38520019","citation_count":49,"is_preprint":false},{"pmid":"9677325","id":"PMC_9677325","title":"Expression and phosphorylation of fibroblast-growth-factor-inducible kinase (Fnk) during cell-cycle progression.","date":"1998","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9677325","citation_count":49,"is_preprint":false},{"pmid":"15640846","id":"PMC_15640846","title":"The Plk3-Cdc25 circuit.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15640846","citation_count":46,"is_preprint":false},{"pmid":"11039900","id":"PMC_11039900","title":"Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11039900","citation_count":45,"is_preprint":false},{"pmid":"16481012","id":"PMC_16481012","title":"Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.","date":"2006","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/16481012","citation_count":45,"is_preprint":false},{"pmid":"27325299","id":"PMC_27325299","title":"Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8.","date":"2016","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27325299","citation_count":38,"is_preprint":false},{"pmid":"26863271","id":"PMC_26863271","title":"Ultrastructural Changes and Corneal Wound Healing After SMILE and PRK Procedures.","date":"2016","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/26863271","citation_count":38,"is_preprint":false},{"pmid":"12606940","id":"PMC_12606940","title":"Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12606940","citation_count":35,"is_preprint":false},{"pmid":"8705713","id":"PMC_8705713","title":"Inflammatory cells, refractive regression, and haze after excimer laser PRK.","date":"1996","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/8705713","citation_count":35,"is_preprint":false},{"pmid":"24702577","id":"PMC_24702577","title":"The U.S. Army Surface Ablation Study: comparison of PRK, MMC-PRK, and LASEK in moderate to high myopia.","date":"2014","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/24702577","citation_count":34,"is_preprint":false},{"pmid":"32905844","id":"PMC_32905844","title":"Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK.","date":"2020","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/32905844","citation_count":32,"is_preprint":false},{"pmid":"24128008","id":"PMC_24128008","title":"Differential binding of RhoA, RhoB, and RhoC to protein kinase C-related kinase (PRK) isoforms PRK1, PRK2, and PRK3: PRKs have the highest affinity for RhoB.","date":"2013","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24128008","citation_count":32,"is_preprint":false},{"pmid":"22828320","id":"PMC_22828320","title":"Investigation on PLK2 and PLK3 substrate recognition.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22828320","citation_count":31,"is_preprint":false},{"pmid":"36476304","id":"PMC_36476304","title":"Losartan Inhibition of Myofibroblast Generation and Late Haze (Scarring Fibrosis) After PRK in Rabbits.","date":"2022","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/36476304","citation_count":31,"is_preprint":false},{"pmid":"18423405","id":"PMC_18423405","title":"ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18423405","citation_count":29,"is_preprint":false},{"pmid":"17068463","id":"PMC_17068463","title":"Corneal ectasia after PRK: clinicopathologic case report.","date":"2006","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/17068463","citation_count":29,"is_preprint":false},{"pmid":"31169612","id":"PMC_31169612","title":"Long-Term Stability With the Athens Protocol (Topography-Guided Partial PRK Combined With Cross-Linking) in Pediatric Patients With Keratoconus.","date":"2019","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/31169612","citation_count":26,"is_preprint":false},{"pmid":"21357687","id":"PMC_21357687","title":"Identification of an interaction between the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor with protein kinase C-related kinase (PRK) 1: implications for prostate cancer.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21357687","citation_count":25,"is_preprint":false},{"pmid":"33514736","id":"PMC_33514736","title":"The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33514736","citation_count":24,"is_preprint":false},{"pmid":"16249101","id":"PMC_16249101","title":"Molecular phylogeny of the palm genus Chamaedorea, based on the low-copy nuclear genes PRK and RPB2.","date":"2005","source":"Molecular phylogenetics and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/16249101","citation_count":24,"is_preprint":false},{"pmid":"31040638","id":"PMC_31040638","title":"Management of progressive keratoconus with partial topography-guided PRK combined with refractive, customized CXL - a novel technique: the enhanced Athens protocol.","date":"2019","source":"Clinical ophthalmology (Auckland, N.Z.)","url":"https://pubmed.ncbi.nlm.nih.gov/31040638","citation_count":24,"is_preprint":false},{"pmid":"17568195","id":"PMC_17568195","title":"Finding Plk3.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17568195","citation_count":22,"is_preprint":false},{"pmid":"24806294","id":"PMC_24806294","title":"Efficient Engraftment of Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells in uPA/SCID Mice by Overexpression of FNK, a Bcl-xL Mutant Gene.","date":"2014","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/24806294","citation_count":22,"is_preprint":false},{"pmid":"18363825","id":"PMC_18363825","title":"Combination therapy with transductive anti-death FNK protein and FK506 ameliorates brain damage with focal transient ischemia in rat.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18363825","citation_count":22,"is_preprint":false},{"pmid":"17467744","id":"PMC_17467744","title":"Transduction of anti-cell death protein FNK protects isolated rat hearts from myocardial infarction induced by ischemia/reperfusion.","date":"2007","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17467744","citation_count":21,"is_preprint":false},{"pmid":"10376213","id":"PMC_10376213","title":"Caenorhabditis elegans contains structural homologs of human prk and plk.","date":"1999","source":"DNA sequence : the journal of DNA sequencing and mapping","url":"https://pubmed.ncbi.nlm.nih.gov/10376213","citation_count":21,"is_preprint":false},{"pmid":"15692606","id":"PMC_15692606","title":"Zonal necrosis prevented by transduction of the artificial anti-death FNK protein.","date":"2005","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/15692606","citation_count":20,"is_preprint":false},{"pmid":"17387707","id":"PMC_17387707","title":"A protein derived from the fusion of TAT peptide and FNK, a Bcl-x(L) derivative, prevents cochlear hair cell death from aminoglycoside ototoxicity in vivo.","date":"2007","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17387707","citation_count":19,"is_preprint":false},{"pmid":"18062778","id":"PMC_18062778","title":"Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18062778","citation_count":19,"is_preprint":false},{"pmid":"23625313","id":"PMC_23625313","title":"Abortive cell cycle events in the brains of scrapie-infected hamsters with remarkable decreases of PLK3/Cdc25C and increases of PLK1/cyclin B1.","date":"2013","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/23625313","citation_count":19,"is_preprint":false},{"pmid":"17178891","id":"PMC_17178891","title":"Endocytic Ark/Prk kinases play a critical role in adriamycin resistance in both yeast and mammalian cells.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17178891","citation_count":19,"is_preprint":false},{"pmid":"29227512","id":"PMC_29227512","title":"Efficacy and Safety Comparison Between Suberoylanilide Hydroxamic Acid and Mitomycin C in Reducing the Risk of Corneal Haze After PRK Treatment In Vivo.","date":"2017","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/29227512","citation_count":19,"is_preprint":false},{"pmid":"24851086","id":"PMC_24851086","title":"Protein Kinase C-Related Kinase (PKN/PRK). Potential Key-Role for PKN1 in Protection of Hypoxic Neurons.","date":"2014","source":"Current neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24851086","citation_count":18,"is_preprint":false},{"pmid":"17959170","id":"PMC_17959170","title":"Anti-apoptotic PTD-FNK protein suppresses lipopolysaccharide-induced acute lung injury in rats.","date":"2007","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17959170","citation_count":17,"is_preprint":false},{"pmid":"18164732","id":"PMC_18164732","title":"Prevention of chemotherapy-induced alopecia by the anti-death FNK protein.","date":"2007","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18164732","citation_count":17,"is_preprint":false},{"pmid":"12459919","id":"PMC_12459919","title":"Cloning and characterisation of PKB and PRK homologs from Hydra and the evolution of the protein kinase family.","date":"2002","source":"Development genes and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/12459919","citation_count":17,"is_preprint":false},{"pmid":"27281822","id":"PMC_27281822","title":"Effect of Hypoxia-regulated Polo-like Kinase 3 (Plk3) on Human Limbal Stem Cell Differentiation.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27281822","citation_count":16,"is_preprint":false},{"pmid":"27344333","id":"PMC_27344333","title":"Overexpression of PLK3 Mediates the Degradation of Abnormal Prion Proteins Dependent on Chaperone-Mediated Autophagy.","date":"2016","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27344333","citation_count":16,"is_preprint":false},{"pmid":"29366414","id":"PMC_29366414","title":"The Acidophilic Kinases PLK2 and PLK3: Structure, Substrate Targeting and Inhibition.","date":"2018","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/29366414","citation_count":15,"is_preprint":false},{"pmid":"19490146","id":"PMC_19490146","title":"Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation.","date":"2009","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19490146","citation_count":15,"is_preprint":false},{"pmid":"15809074","id":"PMC_15809074","title":"The anti-cell death FNK protein protects cells from death induced by freezing and thawing.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15809074","citation_count":15,"is_preprint":false},{"pmid":"20000291","id":"PMC_20000291","title":"Corneal endothelial cell density after femtosecond thin-flap LASIK and PRK for myopia: a contralateral eye study.","date":"2009","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/20000291","citation_count":15,"is_preprint":false},{"pmid":"35783188","id":"PMC_35783188","title":"Inhibition of PLK3 Attenuates Tubular Epithelial Cell Apoptosis after Renal Ischemia-Reperfusion Injury by Blocking the ATM/P53-Mediated DNA Damage Response.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35783188","citation_count":14,"is_preprint":false},{"pmid":"34107258","id":"PMC_34107258","title":"miR-24 controls the regenerative competence of hair follicle progenitors by targeting Plk3.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34107258","citation_count":14,"is_preprint":false},{"pmid":"28108419","id":"PMC_28108419","title":"Regulation of protein kinase C-related kinase (PRK) signalling by the TPα and TPβ isoforms of the human thromboxane A2 receptor: Implications for thromboxane- and androgen- dependent neoplastic and epigenetic responses in prostate cancer.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28108419","citation_count":14,"is_preprint":false},{"pmid":"25666947","id":"PMC_25666947","title":"FRET analysis of CP12 structural interplay by GAPDH and PRK.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25666947","citation_count":13,"is_preprint":false},{"pmid":"11746980","id":"PMC_11746980","title":"Intron/exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines.","date":"2001","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11746980","citation_count":12,"is_preprint":false},{"pmid":"32232973","id":"PMC_32232973","title":"Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.","date":"2020","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/32232973","citation_count":12,"is_preprint":false},{"pmid":"19848379","id":"PMC_19848379","title":"Confocal microscopy of corneal stroma and endothelium after LASIK and PRK.","date":"2009","source":"Journal of refractive surgery (Thorofare, N.J. : 1995)","url":"https://pubmed.ncbi.nlm.nih.gov/19848379","citation_count":12,"is_preprint":false},{"pmid":"37874309","id":"PMC_37874309","title":"PLK3 facilitates replication of swine influenza virus by phosphorylating viral NP protein.","date":"2023","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/37874309","citation_count":11,"is_preprint":false},{"pmid":"22099262","id":"PMC_22099262","title":"Mild hypothermia enhanced the protective effect of protein therapy with transductive anti-death FNK protein using a rat focal transient cerebral ischemia model.","date":"2011","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22099262","citation_count":11,"is_preprint":false},{"pmid":"32575753","id":"PMC_32575753","title":"Phosphorylation of PLK3 Is Controlled by Protein Phosphatase 6.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32575753","citation_count":10,"is_preprint":false},{"pmid":"37134105","id":"PMC_37134105","title":"Parkin-mediated mitophagy is negatively regulated by FOXO3A, which inhibits Plk3-mediated mitochondrial ROS generation in STZ diabetic stress-treated pancreatic β cells.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/37134105","citation_count":10,"is_preprint":false},{"pmid":"26307252","id":"PMC_26307252","title":"Tools to discriminate between targets of CK2 vs PLK2/PLK3 acidophilic kinases.","date":"2012","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/26307252","citation_count":10,"is_preprint":false},{"pmid":"25724737","id":"PMC_25724737","title":"Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.","date":"2015","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25724737","citation_count":9,"is_preprint":false},{"pmid":"35300109","id":"PMC_35300109","title":"Natural COA water inhibits mitochondrial ROS-mediated apoptosis through Plk3 downregulation under STZ diabetic stress in pancreatic β-cell lines.","date":"2022","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/35300109","citation_count":9,"is_preprint":false},{"pmid":"22189415","id":"PMC_22189415","title":"Topical application of the antiapoptotic TAT-FNK protein prevents aminoglycoside-induced ototoxicity.","date":"2011","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22189415","citation_count":8,"is_preprint":false},{"pmid":"19556223","id":"PMC_19556223","title":"Overexpression of Plk3 causes morphological change and cell growth suppression in Ras pathway-activated cells.","date":"2009","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19556223","citation_count":7,"is_preprint":false},{"pmid":"38434880","id":"PMC_38434880","title":"Plk3 Enhances Cisplatin Sensitivity of Nonsmall-Cell Lung Cancer Cells through Inhibition of the PI3K/AKT Pathway via Stabilizing PTEN.","date":"2024","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/38434880","citation_count":7,"is_preprint":false},{"pmid":"37873730","id":"PMC_37873730","title":"TUBA1A licenses APC/C-mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3.","date":"2023","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/37873730","citation_count":7,"is_preprint":false},{"pmid":"17229437","id":"PMC_17229437","title":"Transduction of the anti-apoptotic PTD-FNK protein improves the efficiency of transplantation of bone marrow mononuclear cells.","date":"2007","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17229437","citation_count":7,"is_preprint":false},{"pmid":"20049336","id":"PMC_20049336","title":"A novel platelet activating factor receptor antagonist reduces cell infiltration and expression of inflammatory mediators in mice exposed to desiccating conditions after PRK.","date":"2009","source":"Clinical & developmental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20049336","citation_count":7,"is_preprint":false},{"pmid":"18955736","id":"PMC_18955736","title":"Transduction of anti-cell death protein FNK suppresses graft degeneration after autologous cylindrical osteochondral transplantation.","date":"2008","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/18955736","citation_count":6,"is_preprint":false},{"pmid":"37568042","id":"PMC_37568042","title":"PLK3 promotes the proneural-mesenchymal transition in glioblastoma via transcriptional regulation of C5AR1.","date":"2023","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/37568042","citation_count":6,"is_preprint":false},{"pmid":"22925637","id":"PMC_22925637","title":"Improvement of the post-thaw qualities of Okinawan native Agu pig sperm frozen in an extender supplemented with antiapoptotic PTD-FNK protein.","date":"2012","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/22925637","citation_count":6,"is_preprint":false},{"pmid":"36177381","id":"PMC_36177381","title":"PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer.","date":"2022","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36177381","citation_count":5,"is_preprint":false},{"pmid":"30815621","id":"PMC_30815621","title":"Corneal endothelial damage after simultaneous PRK and corneal cross-linking in stable keratoconus.","date":"2019","source":"American journal of ophthalmology case reports","url":"https://pubmed.ncbi.nlm.nih.gov/30815621","citation_count":4,"is_preprint":false},{"pmid":"25062131","id":"PMC_25062131","title":"Alcohol-assisted debridement in PRK with intraoperative mitomycin C.","date":"2014","source":"Optometry and vision science : official publication of the American Academy of Optometry","url":"https://pubmed.ncbi.nlm.nih.gov/25062131","citation_count":3,"is_preprint":false},{"pmid":"26843517","id":"PMC_26843517","title":"Cytoskeletal architecture and cell motility remain unperturbed in mouse embryonic fibroblasts from Plk3 knockout mice.","date":"2016","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/26843517","citation_count":2,"is_preprint":false},{"pmid":"39457602","id":"PMC_39457602","title":"Comparative Analysis of Corneal Wound Healing: Differential Molecular Responses in Tears Following PRK, FS-LASIK, and SMILE Procedures.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/39457602","citation_count":2,"is_preprint":false},{"pmid":"39837970","id":"PMC_39837970","title":"PLK3 weakens antioxidant defense and inhibits proliferation of porcine Leydig cells under oxidative stress.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39837970","citation_count":1,"is_preprint":false},{"pmid":"16388739","id":"PMC_16388739","title":"[Construction of pMSCV recombinant retroviral vector containing polo-like kinase 3(plk3) cDNA and its effects on cell proliferation].","date":"2006","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16388739","citation_count":1,"is_preprint":false},{"pmid":"39315304","id":"PMC_39315304","title":"Activating transcription factor 3 (ATF3) and calcitonin gene-related peptide (CGRP) increase in trigeminal ganglion neurons in female rats after photorefractive keratectomy (PRK)-like corneal abrasion.","date":"2024","source":"Neurobiology of pain (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/39315304","citation_count":1,"is_preprint":false},{"pmid":"8499362","id":"PMC_8499362","title":"PRK using an absorbing cell delivery system for correction of myopia from 4 to 26 D in 3251 eyes.","date":"1993","source":"Refractive & corneal surgery","url":"https://pubmed.ncbi.nlm.nih.gov/8499362","citation_count":1,"is_preprint":false},{"pmid":"40874686","id":"PMC_40874686","title":"PLK3-Activated Mitochondrial Apoptosis Pathway in the Pathogenesis of Sepsis-Associated Acute Kidney Injury.","date":"2025","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40874686","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52496,"output_tokens":8168,"usd":0.140004,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17668,"output_tokens":7859,"usd":0.142407,"stage2_stop_reason":"end_turn"},"total_usd":0.282411,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"PRK/PLK3 encodes a protein serine/threonine kinase with an N-terminal catalytic domain homologous to polo-family kinases (CDC5, Drosophila polo, PLK1) and a C-terminal regulatory domain; recombinant protein strongly phosphorylates casein but not histone H1 in vitro; expression is induced by serum and cytokines (IL-3, thrombopoietin) in hematopoietic cells without requiring new protein synthesis.\",\n      \"method\": \"cDNA cloning, in vitro kinase assay with recombinant protein, Northern blotting, serum/cytokine stimulation experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase reconstitution with recombinant protein, multiple orthogonal methods (cloning, kinase assay, expression analysis) in a single study\",\n      \"pmids\": [\"8702627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Human PRK/PLK3 phosphorylates Cdc25C in vitro, peaks in kinase activity during late S and G2 phases, potentiates progesterone-induced meiotic maturation of Xenopus oocytes when overexpressed, delays oocyte maturation with antisense transcripts, and rescues the temperature-sensitive CDC5 mutant in S. cerevisiae, establishing a conserved mitotic regulatory role.\",\n      \"method\": \"In vitro kinase assay with recombinant baculovirus-expressed protein, Xenopus oocyte maturation assay, yeast complementation of cdc5 mutant, cell-cycle fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods including in vitro reconstitution, genetic rescue in yeast, and Xenopus functional assay across two model organisms\",\n      \"pmids\": [\"9353331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Fnk/PLK3 protein is present in quiescent cells, increases in abundance from G1 to mitosis, undergoes mitotic-specific phosphorylation that causes a mobility shift and correlates with increased kinase activity; dephosphorylation by phosphatase treatment of mitotic immunoprecipitates reduces this activity, demonstrating phosphorylation-dependent kinase activation.\",\n      \"method\": \"SDS-PAGE mobility shift analysis, phosphatase treatment, immunoprecipitation kinase assay, cell-cycle synchronization\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal biochemical experiments (phosphatase reversal of kinase activation), single lab, two orthogonal methods\",\n      \"pmids\": [\"9677325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Purified recombinant Prk/PLK3 directly phosphorylates Cdc25C in vitro on serine 216 (the major site also targeted by Chk1/Chk2); kinase-defective PrkK52R mutant cannot phosphorylate Cdc25C; Prk and Cdc25C physically interact by co-immunoprecipitation and affinity chromatography; when co-infected with Prk baculovirus, Cdc25C acquires autophosphorylating kinase activity dependent on catalytically active Prk.\",\n      \"method\": \"In vitro kinase assay with purified recombinant baculovirus proteins, co-immunoprecipitation, affinity chromatography, phosphopeptide mapping, active-site mutant (K52R)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with purified recombinant proteins, active-site mutagenesis, co-IP, and phosphopeptide mapping in a single study\",\n      \"pmids\": [\"10557092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Fnk/PLK3 interacts specifically with CIB (Ca2+- and integrin-binding protein) via a conserved C-terminal polo-box domain; Fnk and Snk mRNA levels are dramatically induced in neurons by stimuli that produce long-term potentiation; induced Fnk protein is targeted to dendrites of activated neurons.\",\n      \"method\": \"Two-hybrid screen, co-immunoprecipitation, co-localization in mammalian cells, LTP stimulation paradigms, subcellular fractionation/localization\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and co-localization confirm interaction, LTP induction is physiologically relevant but single lab\",\n      \"pmids\": [\"10523297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Overexpression of PLK3 in mammalian cells induces chromatin condensation, apoptosis, and incomplete cytokinesis; EGFP-Plk3 localizes to the cellular cortex and cell midbody during mitotic exit, consistent with a cytokinesis role; Bcl-2 co-expression cannot block the apoptotic phenotype; the C-terminal domain (but not catalytic activity) is required for apoptosis induction.\",\n      \"method\": \"Transfection/overexpression, EGFP live-cell imaging, TUNEL assay, Bcl-2 co-expression epistasis, deletion/domain mutant analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization by live imaging linked to functional phenotype, domain dissection, single lab\",\n      \"pmids\": [\"11156373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Plk3 physically interacts with p53, and this interaction is enhanced upon DNA damage; recombinant Plk3 phosphorylates a GST-p53 fusion in vitro on serine 20; expression of kinase-defective Plk3(K52R) reduces p53-S20 phosphorylation, decreases p21 levels, and increases cell proliferation; Plk3 kinase activity is rapidly induced by DNA damage in an ATM-dependent manner, while Plk1 activity is reduced; kinase-active Plk3 overexpression induces apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, in vitro kinase assay with recombinant proteins, immunoblotting with phosphospecific antibodies, ATM-dependent activation assay, kinase-dead mutant expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro phosphorylation, pulldown plus Co-IP, active-site mutagenesis with defined downstream functional readout (p21 levels, proliferation)\",\n      \"pmids\": [\"11551930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Plk3 becomes phosphorylated following DNA damage (ATM-dependent) or mitotic spindle disruption (ATM-independent); phosphorylation enhances kinase activity; Plk3 physically associates with Chk2 and p53 and phosphorylates both as substrates; phosphorylated Plk3 also co-elutes with unpolymerized tubulin; Plk3 exists in multiple high-molecular-weight complexes (150–>600 kDa) whose composition changes upon phosphorylation.\",\n      \"method\": \"Sizing column fractionation, immunoprecipitation kinase assay, in vitro phosphorylation with recombinant proteins, ATM inhibition/genetic dependence, tubulin co-elution\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (kinase assay, size fractionation, Co-IP, ATM epistasis) identifying substrates and regulatory inputs\",\n      \"pmids\": [\"12242661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Plk3 is rapidly activated by reactive oxygen species in normal diploid fibroblasts (WI-38), correlating with increased p53 levels; Plk3 physically interacts with Chk2 (enhanced by DNA damage); Chk2 immunoprecipitated from Plk3-expressing (T47D) cells stimulates the in vitro kinase activity of recombinant Plk3 more than Chk2 from Plk3-deficient (Daudi) cells; ectopic Chk2 expression activates cellular Plk3, placing Chk2 upstream of Plk3 in the DNA damage response.\",\n      \"method\": \"In vitro kinase assay with purified recombinant Plk3, co-immunoprecipitation, ectopic Chk2 expression, ROS treatment\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution with immunoprecipitated Chk2 stimulating recombinant Plk3, Co-IP, single lab\",\n      \"pmids\": [\"12548019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Plk3 phosphorylates Cdc25C primarily on S191 and secondarily on S198 in vitro; a phosphomimetic S191D mutant accumulates in the nucleus while S191A facilitates nuclear exclusion; Plk3-WT overexpression drives Cdc25C nuclear accumulation and decreases Cdc2 Y15 phosphorylation; kinase-dead Plk3 overexpression fails to relocalize Cdc25C; the effect is reversed by Plk3 siRNA co-expression.\",\n      \"method\": \"In vitro kinase assay, transfection of phosphomimetic/phospho-null Cdc25C mutants, subcellular localization by immunofluorescence, immunoblotting for Cdc2-Y15, siRNA rescue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro site mapping plus phosphomimetic mutagenesis plus functional rescue by siRNA across multiple orthogonal readouts\",\n      \"pmids\": [\"14968113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Plk3 phosphorylates Chk2 at S62 and S73 in vitro; S73 phosphorylation by Plk3 facilitates subsequent ATM-dependent phosphorylation of Chk2 on T68 in response to DNA damage; Chk2-S73A mutant fails to associate with large complexes in vivo, has reduced kinase activity toward Cdc25C, is inefficiently phosphorylated at T68 by ATM, and cannot maintain G2/M checkpoint (Cdc2-Y15 hypophosphorylated); in Chk2-deficient Daudi cells, Chk2 kinase activity toward Cdc25C is weak and is restored dose-dependently by adding recombinant Plk3.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis (S73A), transfection/rescue, ATM epistasis, immunoprecipitation kinase assay, G2/M checkpoint assay\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — site-specific mutagenesis validated functionally through G2/M checkpoint readout, in vitro reconstitution, genetic epistasis placing Plk3 upstream of ATM-mediated Chk2 activation\",\n      \"pmids\": [\"16481012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The Polo box domain (PBD) of Plk3, requiring both polo boxes, is sufficient for centrosome, spindle pole, and midbody localization; overexpression of the PBD (but not the kinase domain) causes mitotic arrest, cytokinesis defects, and apoptosis; Plk3 PBD is more potent than Plk1 PBD in suppressing proliferation.\",\n      \"method\": \"Ectopic expression of domain constructs, immunofluorescence localization in HeLa and U2OS cells, cell-cycle analysis, apoptosis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization with domain deletions linked to defined mitotic phenotype, single lab\",\n      \"pmids\": [\"16478733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Plk3 interacts with VRK1 (forming a stable complex detected by reciprocal immunoprecipitation and pull-down); VRK1 co-localizes with Plk3 at the Golgi apparatus; Plk3 phosphorylates the C-terminal region of VRK1 specifically at Ser342; VRK1-S342 substitution mutants are catalytically active but block Golgi fragmentation; Plk3 functions downstream of MEK1 and upstream of VRK1 in the Golgi fragmentation pathway; kinase-dead Plk3, VRK1 siRNA, or the MEK1 inhibitor PD98059 all inhibit MEK1/Plk3-induced Golgi fragmentation.\",\n      \"method\": \"Reciprocal co-immunoprecipitation, pull-down, immunofluorescence co-localization, in vitro kinase assay, site-directed mutagenesis (S342), siRNA knockdown, epistasis with MEK1 inhibitor and kinase-dead constructs\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reciprocal Co-IP, in vitro phosphorylation with site identification, mutagenesis with functional (Golgi fragmentation) readout, pathway epistasis by multiple independent perturbations\",\n      \"pmids\": [\"19103756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Plk3 phosphorylates topoisomerase IIα at Thr1342 in vitro using a synthetic peptide and recombinant protein; Thr1342 is not recognized by Plk1; acidic residues at positions +2 and +4 relative to the phosphosite are positive determinants for Plk3 but not Plk1 specificity; Plk3 overexpression induces Thr1342 phosphorylation in cellular topoisomerase IIα; Plk3 and topoisomerase IIα physically interact in cells.\",\n      \"method\": \"In vitro kinase assay with synthetic peptides, co-immunoprecipitation in cells, immunoblotting with phosphospecific antibody, overexpression\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis of substrate determinants plus cellular co-IP validation, single lab\",\n      \"pmids\": [\"18062778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Plk3 physically interacts with p73 (by co-immunoprecipitation and GST pull-down); Plk3 phosphorylates the N-terminal portion of p73 in vitro; Plk3 inhibits p73-mediated transcriptional activity and pro-apoptotic function; kinase-deficient Plk3 fails to inhibit p73, demonstrating kinase-activity dependence; Plk3 reduces p73 protein stability; Plk3 knockdown increases p73 stability and promotes cisplatin-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, in vitro kinase assay, luciferase reporter assay, RT-PCR, kinase-dead mutant, siRNA knockdown, flow cytometry (apoptosis)\",\n      \"journal\": \"Genes to cells : devoted to molecular & cellular mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro phosphorylation plus Co-IP plus kinase-dead epistasis with functional readout, single lab\",\n      \"pmids\": [\"19490146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Plk3 physically interacts with HIF-1α under hypoxia (by immunoprecipitation and pull-down); purified recombinant Plk3, but not a kinase-defective mutant, phosphorylates HIF-1α in vitro causing a major mobility shift; mass spectrometry identified two serine residues as Plk3 phosphorylation sites; phosphomutant HIF-1α has a much longer half-life than wild-type, demonstrating Plk3 promotes HIF-1α degradation; PLK3-null MEFs contain elevated HIF-1α under hypoxia.\",\n      \"method\": \"Immunoprecipitation, pull-down, in vitro kinase assay with purified recombinant Plk3, mass spectrometry, cycloheximide chase/pulse-chase, PLK3-null MEFs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro kinase assay, mass spectrometry site identification, phosphomutant half-life analysis, and genetic null validation (multiple orthogonal methods, one study)\",\n      \"pmids\": [\"20889502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Plk3 phosphorylates PTEN in vitro at Thr366 and Ser370 (identified by mass spectrometry and confirmed by phosphospecific antibody); kinase-defective Plk3 mutant cannot phosphorylate PTEN; PLK3-null MEFs have reduced PTEN levels and increased Akt1 activation; Plk3-targeting PTEN mutants are expressed at reduced levels associated with enhanced PDK1 activity; the reduced PTEN in PLK3-null MEFs is stabilized by the proteasome inhibitor MG132, demonstrating Plk3 phosphorylation stabilizes PTEN.\",\n      \"method\": \"In vitro kinase assay, mass spectrometry, phosphospecific immunoblotting, PLK3-null MEFs, kinase-dead mutant, MG132 proteasome inhibitor treatment, Akt/GSK3β activation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, mass spectrometry site identification, genetic null validation, proteasome inhibitor rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"20940307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In vitro PLK3 phosphorylates HSP90, GRP-94, β-tubulin, calumenin, and 14-3-3 epsilon in cell lysate kinase assays; phosphosites in these substrates were mapped by mass spectrometry and used to define PLK3 substrate consensus determinants as acidophilic (requiring acidic residues surrounding the target Ser/Thr).\",\n      \"method\": \"Cell lysate kinase assay, 2D gel electrophoresis, mass spectrometry substrate identification and phosphosite mapping\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mass spectrometry site identification, single lab, multiple substrates validated\",\n      \"pmids\": [\"22828320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PRK3 HR1a and HR1b domains bind RhoA, RhoB, and RhoC with different affinities; PRK3 HR1b domain uniquely mediates a RhoB-specific interaction requiring both the C-terminus of RhoB and the HR1b domain; RhoB binds all PRK isoforms with higher affinity than RhoA or RhoC; the PRK2/PRK3 HR1 domains generally bind Rho proteins less tightly than PRK1.\",\n      \"method\": \"Quantitative binding affinity measurements (surface plasmon resonance or equivalent), thermal stability assays, domain constructs encompassing HR1a and HR1b\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative binding measurements with domain constructs defining specificity determinants, single lab study\",\n      \"pmids\": [\"24128008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PLK3 is identified as a new interaction partner of the death receptor CD95; PLK3 enzymatic activity increases upon CD95 ligand stimulation; knockout of caspase-8, CD95, or FADD prevents PLK3 activation, establishing requirement for a functional DISC; PLK3 phosphorylates caspase-8 at Thr273, stimulating its pro-apoptotic function; non-phosphorylatable caspase-8-T273A mutant or PLK3 CRISPR/Cas9 knockout reduces caspase-8 processing after CD95 stimulation.\",\n      \"method\": \"Co-immunoprecipitation, CRISPR/Cas9 knockout, kinase activity assay, site-directed mutagenesis (T273A rescue experiment), genetic epistasis (CD95/FADD/caspase-8 KO)\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR KO, mutagenesis rescue, Co-IP, and kinase activity assay with multiple genetic epistasis experiments identifying substrate and pathway position\",\n      \"pmids\": [\"27325299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Hypoxic stress activates Plk3 signaling and c-Jun/AP-1 in corneal epithelial cells leading to apoptosis, but suppresses Plk3 activity at the transcription level in limbal stem cells (HLS), resulting in differentiation instead of apoptosis; hypoxia-induced c-Jun phosphorylation is not observed in HLS cells because Plk3 is suppressed; Plk3-deficient (Plk3-/-) mouse corneas show altered limbal stem cell differentiation and center epithelial apoptosis patterns confirming pathway dependence.\",\n      \"method\": \"Plk3-/- mouse model, DNA fragmentation, TUNEL assay, cell cycle analysis, p63/keratin 12 expression, c-Jun phosphorylation, gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null mouse validated alongside mechanistic measurements in primary cells, single lab\",\n      \"pmids\": [\"27281822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PLK3 interacts with the PP6 (protein phosphatase 6) complex via its polo box domain; PLK3 is phosphorylated at Thr219 in its T-loop; PP6 constantly dephosphorylates Thr219; unlike PLK1, phosphorylation of PLK3-Thr219 does not upregulate enzymatic activity, indicating distinct activation mechanisms between PLK1 and PLK3; CRISPR/Cas9-generated PLK3 knockout cells do not show impaired HIF-1α stabilization under hypoxia, p-c-Jun under osmotic stress, or DNA damage response dynamics.\",\n      \"method\": \"CRISPR/Cas9 knockout in RPE cells, mass spectrometry (PP6 as interactor), immunoprecipitation, in vitro kinase assay with purified EGFP-PLK3, phosphospecific immunoblotting (T219), RNAi knockdown\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mass spectrometry identification of PP6 interaction, in vitro kinase assay, CRISPR KO, single lab; negative findings explicitly noted\",\n      \"pmids\": [\"32575753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PLK3 phosphorylates GOF mutant p53 at serine 20; PLK3 knockout attenuates S20 phosphorylation and reduces transactivation and oncogenicity by GOF p53; GOF p53 TAD mutations (L25Q/W26S) that reduce S20 phosphorylation lose tumorigenicity; these data place PLK3-mediated S20 phosphorylation as mechanistically required for GOF p53-driven oncogenesis.\",\n      \"method\": \"PLK3 knockout mouse model, conditional knock-in alleles (LSL p53-R172H, K-Ras-G12D), phosphospecific immunoblotting for p53-S20, transactivation assays, tumor growth analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout in vivo with phosphospecific readout and functional (tumor) phenotype, single study\",\n      \"pmids\": [\"33514736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PLK3 interacts with viral nucleoprotein (NP) of swine influenza H1N1; PLK3 overexpression increases NP phosphorylation and oligomerization; PLK3 phosphorylates NP at serine 482 (S482), and S482 phosphorylation regulates NP oligomerization, viral polymerase activity, and viral growth.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphorylation assay, site-directed mutagenesis (S482), viral polymerase activity assay, viral growth assay\",\n      \"journal\": \"Emerging microbes & infections\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with site mutagenesis plus functional viral readout, single lab\",\n      \"pmids\": [\"37874309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SETDB1 methylates PLK3 at K106 and K200 (scaffolded by the lncRNA LINC00115); PLK3 methylation decreases PLK3 phosphorylation of HIF1α and increases HIF1α stability in drug-resistant breast cancer stem-like cells; this establishes SETDB1-mediated lysine methylation as a post-translational modification that suppresses PLK3 kinase activity toward HIF1α.\",\n      \"method\": \"RNA pull-down, RNA immunoprecipitation, mass spectrometry, CRISPR/Cas9 knockout, methylation-specific assays, HIF1α stability assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry identification of methylation sites, CRISPR KO, functional HIF1α stability readout; single lab, complex multi-component system\",\n      \"pmids\": [\"38520019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-24 directly targets Plk3 mRNA in hair follicle progenitors; miR-24 upregulation blunts growth responsiveness and retards hair regeneration, while its ablation leads to hyper-sensitized growth responsiveness and precocious hair regeneration; reduced Plk3 downstream of miR-24 leads to decreased CCNE1 (cyclin E1) expression, limiting cell-cycle entry.\",\n      \"method\": \"miR-24 conditional overexpression and ablation in skin epithelium, target validation (miR-24 → Plk3), cell-cycle analysis, CCNE1 expression measurement, in vivo hair regeneration assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic gain- and loss-of-function with direct target validation, in vivo phenotype, single lab\",\n      \"pmids\": [\"34107258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TUBA1A (tubulin alpha 1a) interacts with PLK3 in the cytoplasm and inhibits its activation; this interaction licenses APC/C activation and Foxm1-mediated metaphase-to-anaphase transition; TUBA1A knockdown causes mitotic arrest and reduces GBM tumor growth in a PLK3-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, TUBA1A knockdown, PLK3 activation assays, APC/C activity assays, xenograft tumor growth assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP identifying interaction, functional epistasis from knockdown, but mechanistic detail on PLK3 activation mechanism is limited and single lab\",\n      \"pmids\": [\"37873730\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLK3 (also known as PRK/FNK) is a polo-family serine/threonine kinase activated by ATM-dependent phosphorylation (at T219 in the T-loop, dephosphorylated by PP6) in response to genotoxic and oxidative stress; it phosphorylates a defined set of substrates—including Cdc25C (at S191/S216 to control nuclear translocation and cell cycle entry), p53 (at S20 to stabilize it and activate apoptotic/arrest programs), Chk2 (at S62/S73 to prime ATM-mediated full Chk2 activation), HIF-1α (to promote its proteasomal degradation under hypoxia), PTEN (at T366/S370 to stabilize it and suppress PI3K/Akt signaling), VRK1 (at S342 downstream of MEK1 to drive Golgi fragmentation), topoisomerase IIα (at T1342), caspase-8 (at T273 downstream of CD95/DISC to amplify extrinsic apoptosis), and influenza NP (at S482)—localizing to centrosomes, spindle poles, and the midbody via its polo box domain; it is negatively regulated by SETDB1-mediated methylation (at K106/K200) and by inhibitory interaction with TUBA1A, and is transcriptionally regulated by stress, serum, and cytokines, collectively functioning as a multi-substrate stress-response and cell-cycle checkpoint kinase with tumor-suppressive activity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PLK3 (PRK/FNK) is a polo-family serine/threonine kinase that functions as a multi-substrate effector coupling genotoxic, oxidative, hypoxic, and death-receptor stress signals to cell-cycle checkpoints and apoptosis [#0, #7]. Its catalytic activity is rapidly induced by DNA damage in an ATM-dependent manner and by reactive oxygen species, and is enhanced by mitotic-specific and stress-induced phosphorylation [#2, #6, #7, #8]. Within the DNA-damage checkpoint PLK3 phosphorylates Cdc25C on S191/S216 to control its nuclear accumulation and entry into mitosis, phosphorylates p53 on S20 to stabilize it and drive p21 induction and apoptosis, and primes Chk2 at S62/S73 to facilitate downstream ATM-mediated Chk2 activation and G2/M arrest [#3, #6, #9, #10]; Chk2 itself acts upstream of PLK3 in this circuit [#8]. PLK3 has broad acidophilic substrate specificity and additional targets that extend its reach beyond the checkpoint: it phosphorylates HIF-1\\u03b1 to promote its proteasomal degradation under hypoxia, phosphorylates PTEN at T366/S370 to stabilize it and suppress Akt signaling, phosphorylates topoisomerase II\\u03b1 at T1342, inhibits p73, and phosphorylates caspase-8 at T273 downstream of the CD95 DISC to amplify extrinsic apoptosis [#13, #14, #15, #16, #17, #19]. Its tandem polo-box domain targets the enzyme to centrosomes, spindle poles, and the midbody and is itself sufficient to drive mitotic arrest and apoptosis [#11], and via this domain PLK3 also acts downstream of MEK1 to phosphorylate VRK1 at S342 and drive Golgi fragmentation [#12]. PLK3 is negatively controlled by PP6, which constitutively dephosphorylates its T-loop T219, and by SETDB1-mediated lysine methylation that suppresses its activity toward HIF-1\\u03b1 [#21, #24]. Genetic models establish PLK3 as a determinant of tumor biology and tissue homeostasis, including a requirement for PLK3-mediated p53-S20 phosphorylation in gain-of-function mutant p53 oncogenesis [#22] and a miR-24/PLK3/cyclin E1 axis controlling cell-cycle entry in regenerating tissue [#25].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established PLK3 as a polo-family serine/threonine kinase whose expression is acutely driven by extracellular growth and cytokine signals, framing it as a stimulus-responsive kinase.\",\n      \"evidence\": \"cDNA cloning, in vitro kinase assay on recombinant protein, and serum/cytokine induction in hematopoietic cells\",\n      \"pmids\": [\"8702627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates unidentified at this stage\", \"Casein used as generic substrate, not a real target\", \"Regulation of kinase activity unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined a conserved mitotic regulatory role by showing PLK3 phosphorylates Cdc25C, peaks in S/G2, and functionally substitutes for yeast CDC5.\",\n      \"evidence\": \"In vitro kinase assay, Xenopus oocyte maturation, yeast cdc5 complementation, cell-cycle fractionation\",\n      \"pmids\": [\"9353331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific Cdc25C phosphosites not yet mapped\", \"How PLK3 activity is timed to the cell cycle unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated that PLK3 activity is controlled by phosphorylation, linking mitotic-specific modification to increased catalytic output.\",\n      \"evidence\": \"Mobility-shift analysis, phosphatase reversal of immunoprecipitate kinase activity, cell-cycle synchronization\",\n      \"pmids\": [\"9677325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Activating phosphosite and responsible kinase not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Pinned down Cdc25C serine 216 as a direct PLK3 site and showed physical PLK3-Cdc25C association, connecting PLK3 to the checkpoint phosphosite shared with Chk1/Chk2.\",\n      \"evidence\": \"Purified recombinant kinase assay, K52R kinase-dead mutant, co-IP, affinity chromatography, phosphopeptide mapping\",\n      \"pmids\": [\"10557092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequence of S216 phosphorylation on checkpoint not directly tested\", \"Relationship to Chk1/Chk2 targeting of the same site unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified the C-terminal polo-box domain as a protein-interaction module (binding CIB) and showed stimulus-driven neuronal induction and dendritic targeting, expanding PLK3 beyond cell cycle.\",\n      \"evidence\": \"Two-hybrid screen, co-IP, co-localization, LTP stimulation paradigms\",\n      \"pmids\": [\"10523297\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of CIB binding unknown\", \"Neuronal substrate not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Linked PLK3 to cytokinesis and apoptosis through midbody/cortex localization, and showed the C-terminal domain rather than catalytic activity drives the apoptotic phenotype.\",\n      \"evidence\": \"Overexpression, EGFP live imaging, TUNEL, Bcl-2 epistasis, domain mutants\",\n      \"pmids\": [\"11156373\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression may not reflect endogenous function\", \"Mechanism by which the C-terminal domain triggers apoptosis unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Placed PLK3 in the ATM-dependent DNA-damage response as a direct p53 S20 kinase that stabilizes p53 and enforces growth suppression.\",\n      \"evidence\": \"Co-IP, GST pull-down, in vitro kinase assay, phosphospecific blotting, ATM-dependence, K52R mutant, p21/proliferation readouts\",\n      \"pmids\": [\"11551930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ATM target on PLK3 not mapped\", \"Quantitative contribution to p53 stabilization versus other kinases unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved the regulatory architecture of PLK3 activation by distinguishing ATM-dependent (DNA damage) from ATM-independent (spindle disruption) phosphorylation and identifying Chk2 and p53 as substrates within high-molecular-weight complexes.\",\n      \"evidence\": \"Sizing-column fractionation, IP kinase assays, in vitro phosphorylation, ATM epistasis, tubulin co-elution\",\n      \"pmids\": [\"12242661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Composition of the >600 kDa complexes not defined\", \"Direct activating phosphosite still unmapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed reciprocal regulation with Chk2, placing Chk2 upstream as an activator of PLK3 during the oxidative/DNA-damage response.\",\n      \"evidence\": \"ROS treatment, in vitro kinase assay with immunoprecipitated Chk2 stimulating recombinant PLK3, co-IP, ectopic Chk2 expression\",\n      \"pmids\": [\"12548019\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Chk2 activates PLK3 directly or via complex assembly unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established the functional output of PLK3-Cdc25C phosphorylation by mapping S191/S198 and showing phosphorylation controls Cdc25C nuclear accumulation and Cdc2-Y15 status.\",\n      \"evidence\": \"In vitro kinase assay, phosphomimetic/phospho-null Cdc25C mutants, immunofluorescence, Cdc2-Y15 blotting, siRNA rescue\",\n      \"pmids\": [\"14968113\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous timing of PLK3 action on Cdc25C during checkpoint recovery not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Positioned PLK3 upstream of ATM-mediated Chk2 activation by showing PLK3 phosphorylation of Chk2 S73 primes T68 phosphorylation and is required for G2/M checkpoint maintenance.\",\n      \"evidence\": \"In vitro kinase assay, S73A mutant, rescue, ATM epistasis, IP kinase assay, G2/M checkpoint assay, recombinant PLK3 rescue in Chk2-deficient cells\",\n      \"pmids\": [\"16481012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of PLK3 vs ATM action in vivo not fully time-resolved\", \"How PLK3 itself becomes activated upstream of Chk2 unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the tandem polo-box domain as both the localization determinant (centrosome/spindle pole/midbody) and a sufficient driver of mitotic arrest and apoptosis.\",\n      \"evidence\": \"Domain construct expression, immunofluorescence in HeLa/U2OS, cell-cycle and apoptosis assays\",\n      \"pmids\": [\"16478733\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphopeptide ligands recognized by the PBD in vivo not identified\", \"Overexpression-based phenotypes\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended PLK3 signaling to Golgi dynamics by identifying VRK1-S342 as a substrate and placing PLK3 between MEK1 and VRK1 in the Golgi fragmentation pathway.\",\n      \"evidence\": \"Reciprocal co-IP, pull-down, co-localization, in vitro kinase assay, S342 mutagenesis, siRNA, MEK1 inhibitor epistasis\",\n      \"pmids\": [\"19103756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger for MEK1-PLK3-VRK1 Golgi pathway unclear\", \"How PLK3 is recruited to Golgi not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined PLK3 acidophilic substrate specificity by mapping topoisomerase II\\u03b1 T1342 and showing the +2/+4 acidic determinants distinguish PLK3 from PLK1.\",\n      \"evidence\": \"In vitro kinase assay with synthetic peptides, co-IP, phosphospecific blotting, overexpression\",\n      \"pmids\": [\"18062778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular consequence of T1342 phosphorylation on topoisomerase II\\u03b1 function not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed PLK3 negatively regulates the p53-family member p73 by phosphorylation, reducing its stability and pro-apoptotic transcriptional activity.\",\n      \"evidence\": \"Co-IP, GST pull-down, in vitro kinase assay, luciferase reporter, kinase-dead mutant, siRNA, flow cytometry\",\n      \"pmids\": [\"19490146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosite on p73 not mapped\", \"Reconciliation with PLK3 pro-apoptotic roles elsewhere unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected PLK3 to hypoxia by showing it phosphorylates HIF-1\\u03b1 to promote its degradation, with genetic null cells accumulating HIF-1\\u03b1.\",\n      \"evidence\": \"IP/pull-down, recombinant kinase assay, mass spectrometry sites, half-life analysis, PLK3-null MEFs\",\n      \"pmids\": [\"20889502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking phosphorylation to proteasomal targeting not detailed\", \"Later KO study found no HIF-1\\u03b1 phenotype, indicating context dependence\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified PLK3 as a positive regulator of PTEN stability via T366/S370 phosphorylation, linking it to suppression of PI3K/Akt signaling.\",\n      \"evidence\": \"In vitro kinase assay, mass spectrometry, phosphospecific blotting, PLK3-null MEFs, MG132 rescue, Akt/GSK3\\u03b2 assays\",\n      \"pmids\": [\"20940307\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase/proteasomal machinery acting on unphosphorylated PTEN not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Generalized the PLK3 acidophilic consensus by identifying additional in vitro substrates (HSP90, GRP-94, \\u03b2-tubulin, calumenin, 14-3-3\\u03b5) and mapping their phosphosites.\",\n      \"evidence\": \"Cell-lysate kinase assay, 2D gel, mass spectrometry phosphosite mapping\",\n      \"pmids\": [\"22828320\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of these substrates not tested\", \"Lysate assay may capture indirect phosphorylation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Characterized Rho-binding specificity of PRK3 HR1 domains, defining a RhoB-selective interaction module.\",\n      \"evidence\": \"Quantitative binding affinity measurements and thermal stability assays with HR1a/HR1b constructs\",\n      \"pmids\": [\"24128008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Rho binding for PLK3 signaling unaddressed\", \"Note: this finding may reflect a distinct PRK protein family and is not integrated with the kinase activity literature\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed PLK3 within extrinsic apoptosis as a DISC-dependent caspase-8 T273 kinase that amplifies CD95-induced cell death.\",\n      \"evidence\": \"Co-IP, CRISPR/Cas9 KO, kinase activity assay, T273A rescue, CD95/FADD/caspase-8 KO epistasis\",\n      \"pmids\": [\"27325299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DISC formation activates PLK3 catalytically not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated cell-type-specific hypoxic outcomes governed by PLK3 transcriptional control, dictating apoptosis versus differentiation in corneal epithelium.\",\n      \"evidence\": \"Plk3-/- mouse corneas, TUNEL, cell-cycle analysis, p63/keratin 12 and c-Jun phosphorylation readouts\",\n      \"pmids\": [\"27281822\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional regulators suppressing Plk3 in limbal stem cells not identified\", \"Direct substrate driving c-Jun phosphorylation unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revised the PLK3 activation model by identifying PP6 as a T-loop (T219) phosphatase and showing, unlike PLK1, T219 phosphorylation does not boost activity; CRISPR KO failed to reproduce several reported stress phenotypes.\",\n      \"evidence\": \"CRISPR KO in RPE cells, mass spectrometry (PP6), IP, recombinant kinase assay, T219 phosphospecific blotting, RNAi\",\n      \"pmids\": [\"32575753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Discrepancy with earlier HIF-1\\u03b1/DNA-damage phenotypes unresolved\", \"True T-loop activation mechanism of PLK3 still undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established PLK3-mediated p53-S20 phosphorylation as mechanistically required for gain-of-function mutant p53 oncogenesis in vivo.\",\n      \"evidence\": \"PLK3 KO mouse, conditional LSL p53-R172H/K-Ras-G12D alleles, p53-S20 phosphospecific blotting, transactivation and tumor growth assays\",\n      \"pmids\": [\"33514736\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How the same S20 phosphorylation supports both tumor suppression and GOF oncogenesis context-dependently unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a miR-24/PLK3/cyclin E1 axis controlling cell-cycle entry and tissue regeneration in hair follicle progenitors.\",\n      \"evidence\": \"miR-24 conditional gain/loss of function, target validation, CCNE1 measurement, in vivo hair regeneration assay\",\n      \"pmids\": [\"34107258\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PLK3 substrate linking to CCNE1 induction not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed PLK3 phosphorylates influenza nucleoprotein at S482 to regulate NP oligomerization, polymerase activity, and viral growth, identifying a host-kinase role in viral replication.\",\n      \"evidence\": \"Co-IP, in vitro phosphorylation, S482 mutagenesis, polymerase and viral growth assays\",\n      \"pmids\": [\"37874309\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PLK3 is recruited to viral ribonucleoprotein in infected cells not shown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Proposed TUBA1A as a cytoplasmic inhibitor of PLK3 that gates APC/C and Foxm1-driven mitotic transition in glioblastoma.\",\n      \"evidence\": \"Co-IP, TUBA1A knockdown, PLK3 activation assays, APC/C assays, xenograft growth\",\n      \"pmids\": [\"37873730\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Mechanism of PLK3 activation/inhibition by TUBA1A poorly defined\", \"Single lab, Co-IP without reciprocal validation\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified SETDB1-mediated lysine methylation (K106/K200), scaffolded by lncRNA LINC00115, as a post-translational brake on PLK3 activity toward HIF-1\\u03b1 in drug-resistant breast cancer stem-like cells.\",\n      \"evidence\": \"RNA pull-down/RIP, mass spectrometry, CRISPR KO, methylation-specific and HIF-1\\u03b1 stability assays\",\n      \"pmids\": [\"38520019\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How methylation mechanistically impairs catalysis not defined\", \"Complex multi-component system, single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The true physiological activation mechanism of PLK3 and the reconciliation of conflicting stress-response phenotypes across genetic models remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Activating upstream kinase/event for endogenous PLK3 unmapped given that T219 phosphorylation does not enhance activity\", \"Discrepancy between PLK3-null MEF phenotypes and CRISPR KO negative results for HIF-1\\u03b1/DNA damage unexplained\", \"Structural basis of polo-box-mediated substrate/localization targeting not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 6, 9, 10, 12, 13, 15, 16, 19]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 3, 17]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [7, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7, 26]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 9, 10, 26]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [6, 7, 10]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 19, 20]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [7, 8, 15, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 16]}\n    ],\n    \"complexes\": [\"PP6 phosphatase complex\"],\n    \"partners\": [\"CDC25C\", \"TP53\", \"CHEK2\", \"VRK1\", \"HIF1A\", \"PTEN\", \"CASP8\", \"PPP6C\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}